

Synergy Score									
		VS-6766 + BRAFI				MEKi + BRAFI			
Cell line	MAPK alteration	PAM alterations	VS-6766 + vemurafenib	VS-6766 + dabrafenib	VS-6766 + encorafenib	cobimetinib + vemurafenib	trametinib + dabrafenib	binimetinib + encorafenib	
A2058	BRAF V600E	PIK3R6	17.615	15.797	17.747	6.682	-5.699	13.419	
IGR-1	BRAF V600E	PIK3C2G, PIK3R5, PIK3CG	16.434	9.543	13.119	14.073	-4.811	9.565	
SK-MEL-5	BRAF V600E	PIK3CB, PIK3C2A, RICTOR	12.431	3.829	9.094	0.564	-7.886	8.691	
WM-266-4	BRAF V600E		6.114	4.522	6.603	1.568	1.025	3.527	
C32	BRAF V600E	PIK2CB, mTOR	11.793	9.287	9.268	3.14	0.466	7.802	



FIG. 1




FIG. 2




FIG. 3




FIG. 4




FIG. 5




FIG. 6




FIG. 7




FIG. 8